Huntsman Cancer Institute | Strategic Alliance Partners

Latest from Huntsman Cancer Institute

Breast Cancer: Chaired by Christos Vaklavas, MD

January 12, 2021

Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of breast cancer.

Dr. Agarwal on Data With Cabozantinib/Atezolizumab in mCRPC

May 07, 2020

Neeraj Agarwal, MD, director of the Genitourinary Oncology Program, Oncology Division, professor of medicine, physician, and investigator, at Huntsman Cancer Institute, discusses data with the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in patients with metastatic castration-resistant prostate cancer (mCRPC).